Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban Granules PK in Children with Thrombosis
NCT02497716Phase 1Completed
- Sponsor
- Bayer
- Start
- Nov 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label, single-arm trial of rivaroxaban in thrombosis, sponsored by Bayer. Primary endpoints: Area Under the Curve and Maximum Observed Drug Concentration. Started Nov 2015; status: completed.
02
Drugs
rivaroxaban
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT02497716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02497716.